Hauck-Dlimi Barbara, Ruppel Renate, Zimmermann Robert, Strobel Julian, Reil Angelika, Eckstein Reinhold, Zingsem Juergen
Department of Transfusion Medicine and Hemostaseology.
Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany.
Transfusion. 2016 Jan;56(1):84-90. doi: 10.1111/trf.13333. Epub 2015 Sep 21.
Neutrophil alloantibodies are well-known triggers of transfusion-related acute lung injury (TRALI) and also cause immune neutropenia. Alloimmune neutropenia due to transfusion is an isolated phenomenon that is only rarely identified. Its incidence is specified in the literature as being less than one in 10,000 transfused plasma-containing units. We expect that this phenomenon is underreported.
We observed five cases of alloimmune neutropenia with no respiratory complications with only one case initially reported as a suspected transfusion reaction. The other four cases were detected in the course of the subsequent lookback investigation.
The first case was reported as a potential transfusion reaction when a female patient showed a decrease in the white blood cell count after a platelet (PLT) transfusion. Examinations of the donor blood revealed an antibody against the human neutrophil antigen HNA-1b; the recipient was typed HNA-1b positive and HNA-1a negative. After examining the blood counts of other patients who previously received PLT concentrates from the same donor, we identified four other patients with an unreported decrease in the leukocyte and/or granulocyte count of more than approximately 50% after transfusion.
HNA antibodies are generally regarded as potential triggers of TRALI. Here we describe an HNA antibody that reproducibly caused transfusion-related neutropenia only without pulmonary complications. Factors predisposing patients to TRALI development are widely discussed. Our case suggests that antibody characteristics are also relevant in the development of TRALI. Current measures to prevent TRALI should also prevent transfusion-related alloimmune neutropenia.
中性粒细胞同种抗体是输血相关急性肺损伤(TRALI)的已知触发因素,也会导致免疫性中性粒细胞减少。输血引起的同种免疫性中性粒细胞减少是一种孤立现象,很少被识别。其发病率在文献中被确定为每10000个输注含血浆单位中少于1例。我们预计这种现象报告不足。
我们观察到5例同种免疫性中性粒细胞减少且无呼吸并发症的病例,最初仅1例报告为疑似输血反应。其他4例在后续回顾性调查过程中被发现。
第一例报告为潜在输血反应,一名女性患者在输注血小板(PLT)后白细胞计数下降。对供血者血液检测发现一种针对人类中性粒细胞抗原HNA-1b的抗体;受血者血型为HNA-1b阳性、HNA-1a阴性。在检查了其他先前接受来自同一供血者的PLT浓缩物的患者的血细胞计数后,我们发现另外4例患者在输血后白细胞和/或粒细胞计数未报告性下降超过约50%。
HNA抗体通常被视为TRALI的潜在触发因素。在此我们描述一种HNA抗体,其可重复性地仅导致输血相关中性粒细胞减少而无肺部并发症。广泛讨论了使患者易发生TRALI的因素。我们的病例提示抗体特征在TRALI的发生中也起作用。当前预防TRALI的措施也应预防输血相关同种免疫性中性粒细胞减少。